Objective: Psychiatric deprescribing is an intervention where psychiatric medications are reduced or discontinued with the goal to improve health and reduce unnecessary risks. The purpose of this study was to synthesize the literature related to psychiatric deprescribing to discuss practice and research implications.
Methods: A structured search of the literature was conducted from May to September 2022, yielding 29 articles meeting inclusion criteria. Articles were reviewed and synthesized.
Results: Psychiatric deprescribing is a complex process with many potential facilitators and barriers. The extant literature provides insight into current gaps in knowledge and implications for clinical practice and research.
Conclusions: In current clinical practice, psychiatric deprescribing is a priority but there are significant barriers. Several areas of future research could be pursued to better support evidence-based practice in this area.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1177/10783903231185353 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Deprescribing antidepressants: An integral and neglected component of high-quality prescribing practice.
Australas Psychiatry
December 2024
Institute of Pharmaceutical Sciences, King's College London, London, UK.
The Effects of Prescribed Medications on Depressive Symptoms and Neurocognitive Performance in People With Human Immunodeficiency Virus (HIV).
Clin Infect Dis
December 2024
Department of Medicine, University of California, San Diego, California, USA.
Background: Alterations in brain function and structure, such as depression and neurocognitive impairment, continue to occur in people with human immunodeficiency virus (HIV, PWH) taking suppressive antiretroviral therapy (ART). The lifespan of PWH has improved but the healthspan remains worse than people without HIV, in part because of aging-related diseases. As a result, polypharmacy is common and increases the risk of drug-drug interactions and adverse reactions.
View Article and Find Full Text PDFRates and predictors of opioid deprescribing after fracture: A retrospective study of Medicare fee-for-service claims.
J Am Geriatr Soc
December 2024
Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, USA.
Article Synopsis
- - The study focuses on opioid discontinuation rates and their predictors among older adults (65+) with Alzheimer's disease-related dementias (ADRD) or frailty who had undergone a fracture and started opioid treatment.
- - It analyzed 33,027 Medicare beneficiaries and found that about 81-83% of non-frail individuals discontinued opioids within 30 days, while those with frailty or ADRD had lower discontinuation rates (76%-77%).
- - Those with both ADRD and frailty were less likely to discontinue opioids compared to those without these conditions, indicating different opioid management needs based on health status.
Deprescribing anticholinergics to preserve brain health: reducing the risk of dementia through deprescribing (R2D2): study protocol for a randomized clinical trial.
Trials
November 2024
Indiana University Center for Aging Research, Regenstrief Institute, Inc, Indianapolis, IN, USA.
Background: Older adults commonly experience chronic medical conditions and are at risk of cognitive impairment as a result of age, chronic comorbidity, and medications prescribed to manage multiple chronic conditions. Anticholinergic medications are common treatments for chronic conditions and have been repeatedly associated with poor cognitive outcomes, including delirium and dementia, in epidemiologic studies. However, no study has definitively evaluated the causal relationship between anticholinergics and cognition in a randomized controlled trial design.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!